MSTN

Across TCGA pan-cancer cohorts, MSTN Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MSTN data layer compared with 25 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MSTN Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MSTN expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, UCEC, and SARC are the cancer types where MSTN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.093	0.690	<.001	54	view →
UCEC	DFS	Median	All	1.000	0.629	.023	26	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
LUSC	OS	Median	III,IV	0.112	0.664	.031	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MSTN–STAD (OS)

Open the STAD breakdown →